Cencora plans to spend $1 billion over the next 5 years to expand its operations in the U.S., including opening a second ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

In just its fifth full quarter on the market, the world’s first treatment for metabolic dysfunction-associated ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia (TD). | Teva Pharmaceuticals has a new ...

Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that ...

The Trump administration has spent much of this year working to coerce drugmakers into lowering their prices in the U.S. | ...

Katie Swicegood Fulp is a bit of a late arrival to the world of pharma marketing. | In a Q&A for Fierce Pharma Marketing’s ...

Teva has issued a voluntary recall of more than 500,000 bottles of the widely used blood pressure medication prazosin ...

Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or ...